CatalystFDA/Bio

BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

Trial failure triggers 8% BioNTech drop, 6% Moderna decline, sector-wide negative readthrough.

What changed

Trial failure triggers 8% BioNTech drop, 6% Moderna decline, sector-wide negative readthrough.

Why it matters

Trial failure triggers 8% BioNTech drop, 6% Moderna decline, sector-wide negative readthrough. — impact context not separately stored; see What changed.

Sources

eodhd